Pear Therapeutics, Inc.

OTCPK:PEAR.Q Stock Report

Market Cap: US$142.0

Pear Therapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure1.3yrs
Board average tenureno data

Recent management updates

Recent updates

Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch

Apr 17
Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch

Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue

Aug 18

Pear Therapeutics providing Core Behavioral with opioid use disorder digital therapeutic

Aug 03

Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction

May 21

Pear Therapeutics Guiding For Being 1% Down The Potential Runway In Current Markets

Apr 04

Even With Low Penetration Assumptions For PDTs, Pear Therapeutics Is A Buy

Jan 10

CEO

Pear Therapeutics has no CEO, or we have no data on them.

Leadership Team

NamePositionTenureCompensationOwnership
Corey McCann
Founder & Directorno dataUS$702.45k7.62%
$ 10.8
Ellen Snow
VP & Chief Accounting Officer1.3yrsno data0.016%
$ 0.02
Ilya Gluhovsky
VP & Chief Technology Officer1.2yrsno datano data
Meara Murphy
Senior Director of Corporate Communicationsno datano datano data
Chris Valosky
VP of Sales1.3yrsno datano data
Martha Carruthers
Vice President of Corporate Developmentno datano datano data
Yuri Maricich
Chief Medical Officer & Head of Development6.6yrsno data0.066%
$ 0.09
Erin Brenner
Chief Product Development Officer3.9yrsno data0.030%
$ 0.04

1.3yrs

Average Tenure

46.5yo

Average Age

Experienced Management: PEAR.Q's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/27 01:59
End of Day Share Price 2024/05/27 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pear Therapeutics, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael ChernyBofA Global Research
Michael GormanBTIG
Marie ThibaultBTIG